Cargando…
Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018
It is unclear how treatment advances impacted the population‐level survival of patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM). Therefore, we assessed trends in first‐line therapy and relative survival (RS) among patients with LPL/WM diagnosed in the Netherlands betw...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292034/ https://www.ncbi.nlm.nih.gov/pubmed/34605017 http://dx.doi.org/10.1111/bjh.17856 |
_version_ | 1784749273784516608 |
---|---|
author | Amaador, Karima Kersten, Marie José Visser, Otto Brink, Mirian Posthuma, Eduardus F. M. Minnema, Monique C. Vos, Josephine M. I. Dinmohamed, Avinash G. |
author_facet | Amaador, Karima Kersten, Marie José Visser, Otto Brink, Mirian Posthuma, Eduardus F. M. Minnema, Monique C. Vos, Josephine M. I. Dinmohamed, Avinash G. |
author_sort | Amaador, Karima |
collection | PubMed |
description | It is unclear how treatment advances impacted the population‐level survival of patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM). Therefore, we assessed trends in first‐line therapy and relative survival (RS) among patients with LPL/WM diagnosed in the Netherlands between 1989 and 2018 (N = 6232; median age, 70 years; 61% males) using data from the nationwide Netherlands Cancer Registry. Patients were grouped into three age groups (<65, 66–75 and >75 years) and four calendar periods. Overall, treatment with anti‐neoplastic agents within 1 year post‐diagnosis gradually decreased over time, following a broader application of an initial watch‐and‐wait approach. Approximately 40% of patients received anti‐neoplastic therapy during 2011–2018. Furthermore, use of chemotherapy alone decreased over time, following an increased application of chemoimmunotherapy. Detailed data among 1596 patients diagnosed during 2014–2018 revealed that dexamethasone‐rituximab‐cyclophosphamide was the most frequently applied regimen; its use increased from 14% to 39% between 2014 and 2018. The 5‐year RS increased significantly over time, particularly since the introduction of rituximab in the early–mid 2000s. The 5‐year RS during 1989–1995 was 75%, 65%, and 46% across the age groups compared to 93%, 85%, and 79% during 2011–2018. However, the survival improvement was less pronounced after 2011. Collectively, the impressive survival improvement may be accounted for by broader application of rituximab‐containing therapy. The lack of survival improvement in the post‐rituximab era warrants studies across multiple lines of therapy to further improve survival in LPL/WM. |
format | Online Article Text |
id | pubmed-9292034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92920342022-07-20 Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018 Amaador, Karima Kersten, Marie José Visser, Otto Brink, Mirian Posthuma, Eduardus F. M. Minnema, Monique C. Vos, Josephine M. I. Dinmohamed, Avinash G. Br J Haematol Haematological malignancy–Clinical It is unclear how treatment advances impacted the population‐level survival of patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM). Therefore, we assessed trends in first‐line therapy and relative survival (RS) among patients with LPL/WM diagnosed in the Netherlands between 1989 and 2018 (N = 6232; median age, 70 years; 61% males) using data from the nationwide Netherlands Cancer Registry. Patients were grouped into three age groups (<65, 66–75 and >75 years) and four calendar periods. Overall, treatment with anti‐neoplastic agents within 1 year post‐diagnosis gradually decreased over time, following a broader application of an initial watch‐and‐wait approach. Approximately 40% of patients received anti‐neoplastic therapy during 2011–2018. Furthermore, use of chemotherapy alone decreased over time, following an increased application of chemoimmunotherapy. Detailed data among 1596 patients diagnosed during 2014–2018 revealed that dexamethasone‐rituximab‐cyclophosphamide was the most frequently applied regimen; its use increased from 14% to 39% between 2014 and 2018. The 5‐year RS increased significantly over time, particularly since the introduction of rituximab in the early–mid 2000s. The 5‐year RS during 1989–1995 was 75%, 65%, and 46% across the age groups compared to 93%, 85%, and 79% during 2011–2018. However, the survival improvement was less pronounced after 2011. Collectively, the impressive survival improvement may be accounted for by broader application of rituximab‐containing therapy. The lack of survival improvement in the post‐rituximab era warrants studies across multiple lines of therapy to further improve survival in LPL/WM. John Wiley and Sons Inc. 2021-10-03 2022-02 /pmc/articles/PMC9292034/ /pubmed/34605017 http://dx.doi.org/10.1111/bjh.17856 Text en © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Haematological malignancy–Clinical Amaador, Karima Kersten, Marie José Visser, Otto Brink, Mirian Posthuma, Eduardus F. M. Minnema, Monique C. Vos, Josephine M. I. Dinmohamed, Avinash G. Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018 |
title | Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018 |
title_full | Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018 |
title_fullStr | Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018 |
title_full_unstemmed | Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018 |
title_short | Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in the Netherlands, 1989–2018 |
title_sort | primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/waldenström macroglobulinaemia: a population‐based study in the netherlands, 1989–2018 |
topic | Haematological malignancy–Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292034/ https://www.ncbi.nlm.nih.gov/pubmed/34605017 http://dx.doi.org/10.1111/bjh.17856 |
work_keys_str_mv | AT amaadorkarima primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018 AT kerstenmariejose primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018 AT visserotto primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018 AT brinkmirian primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018 AT posthumaeduardusfm primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018 AT minnemamoniquec primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018 AT vosjosephinemi primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018 AT dinmohamedavinashg primarytherapyandrelativesurvivalinpatientswithlymphoplasmacyticlymphomawaldenstrommacroglobulinaemiaapopulationbasedstudyinthenetherlands19892018 |